BamSEC and AlphaSense Join Forces
Learn More

Viking Therapeutics Inc. – Material Contracts

NASDAQ: VKTX    
Share price (8/7/26): $34.26    
Market cap (8/7/26): $3.997 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 14 pages Employment Agreement
12/34/56
EX-10.2
from 10-Q 11 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 29 pages Viking Therapeutics, Inc. Common Stock ($0.00001 Par Value Per Share) At-The-Market Equity Offering Sales Agreement
12/34/56
EX-10.1
from 10-Q 14 pages Employment Agreement
12/34/56
EX-10.19
from 10-K 6 pages ***Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Amendment No. 3 to Common Stock Purchase Agreement
12/34/56
EX-10.18
from 10-K 6 pages ***Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Amendment No. 2 to Common Stock Purchase Agreement
12/34/56
EX-10.12
from 10-K 5 pages Viking Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.3
from 10-Q 65 pages ***Certain Identified Information Has Been Omitted Pursuant to Item 601(b)(10) of Regulation S-K Because Such Information Is Both (I) Not Material and (II) Information That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Manufacturing and Supply (Drug Product) Agreement
12/34/56
EX-10.2
from 10-Q 29 pages ***Certain Identified Information Has Been Omitted Pursuant to Item 601(b)(10) of Regulation S-K Because Such Information Is Both (I) Not Material and (II) Information That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Prepayment Agreement Between Viking Therapeutics Ireland Limited as Purchaser, and Corden Pharma Schweizerhalle Gmbh, Corden Pharma Gmbh, and Corden Pharma Colorado, Inc. as Supplier
12/34/56
EX-10.1
from 10-Q 63 pages ***Certain Identified Information Has Been Omitted Pursuant to Item 601(b)(10) of Regulation S-K Because Such Information Is Both (I) Not Material and (II) Information That the Registrant Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Strategic Manufacturing and Supply Agreement
12/34/56
EX-10.16
from 10-K 25 pages ***Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Viking Therapeutics, Inc. Common Stock Purchase Agreement
12/34/56
EX-10.12
from 10-K 5 pages Viking Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.11
from 10-K 16 pages Employment Agreement
12/34/56
EX-10.10
from 10-K 14 pages Employment Agreement
12/34/56
EX-10.3
from 10-Q 18 pages ***Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** Second Amendment to Master License Agreement
12/34/56
EX-10.2
from 10-Q 6 pages ***Certain Identified Information Has Been Excluded From the Exhibit Because It Both (I) Is Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit.*** First Amendment to Master License Agreement
12/34/56
EX-10.1
from 10-Q 61 pages Recitals
12/34/56
EX-10.11
from 10-K 5 pages Viking Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 13 pages Amendment No. 1 to At-The-Market Equity Offering Sales Agreement
12/34/56
EX-10.1
from 8-K 24 pages Viking Therapeutics, Inc. Common Stock ($0.00001 Par Value Per Share) At-The-Market Equity Offering Sales Agreement
12/34/56